Impact of Concomitant Medication Administered at the Time of
Initiation of Nivolumab Therapy on Outcome in Non-small Cell
Lung Cancer

J 2020

Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer

SVATON, Martin, Milada ZEMANOVA, Petra ZEMANOVA, Juraj KULTAN, Ondrej FISCHER et. al.

Základní údaje

Originální název

Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer

Autoři

SVATON, Martin (203 Česká republika, garant), Milada ZEMANOVA (203 Česká republika), Petra ZEMANOVA (203 Česká republika), Juraj KULTAN (203 Česká republika), Ondrej FISCHER (203 Česká republika), Jana SKŘIČKOVÁ (203 Česká republika, domácí), Lenka JAKUBÍKOVÁ (203 Česká republika, domácí), Marketa CERNOVSKA (203 Česká republika), Michal HRNCIARIK (203 Česká republika), Michal JIROUSEK (203 Česká republika), Jana KREJCI (203 Česká republika), Daniel KREJCI (203 Česká republika), Ondřej BÍLEK (203 Česká republika, domácí), Jiri BLAZEK (203 Česká republika), Karolína HURDÁLKOVÁ (203 Česká republika, domácí), Magda BAŘINOVÁ (203 Česká republika, domácí) a Bohuslav MELICHAR (203 Česká republika)

Vydání

Anticancer Research, Athens, International Institute of Anticancer Research, 2020, 0250-7005

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.480

Kód RIV

RIV/00216224:14110/20:00115906

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.21873/anticanres.14182

UT WoS

000522734400050

Klíčová slova anglicky

Nivolumab; non-small cell lung cancer; corticoids; antibiotics; proton pump inhibitors; NSAID; statins; metformin

Štítky

14110215, 14110811, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 3. 7. 2020 12:50, Mgr. Tereza Miškechová

Anotace

V originále

Aim: To investigate potential association between administration of corticosteroids, antibiotics, probiotics, proton pump inhibitors, non-steroidal anti-inflammatory drugs (NSAID), statins and metformin and outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Patients and Methods: A total of 224 patients with advanced NSCLC treated at nine comprehensive cancer centers were analyzed in this national retrospective study. Survival statistics were evaluated using Kaplan-Meier method and Cox analysis. Results: Only corticosteroid use had a significant negative effect on the objective response rate. In the univariate analysis, there was no significant effect of the studied concomitant medications on the efficacy of nivolumab. In a subsequent multifactorial analysis, a possible positive effect of the concomitant use of NSAID at the initiation of nivolumab treatment was revealed. Conclusion: The results of the present retrospective exploratory analysis underscore the importance of knowing the exact type of concomitant medication, the route of administration, the dose of medication, and the region of the ongoing study. The present data indicated a significantly higher rate of progression in patients treated with corticosteroids and the possible positive effect of NSAID use at the initiation of nivolumab treatment.

Citovat

SVATON, Martin, Milada ZEMANOVA, Petra ZEMANOVA, Juraj KULTAN, Ondrej FISCHER, Jana SKŘIČKOVÁ, Lenka JAKUBÍKOVÁ, Marketa CERNOVSKA, Michal HRNCIARIK, Michal JIROUSEK, Jana KREJCI, Daniel KREJCI, Ondřej BÍLEK, Jiri BLAZEK, Karolína HURDÁLKOVÁ, Magda BAŘINOVÁ a Bohuslav MELICHAR. Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer. Anticancer Research. Athens: International Institute of Anticancer Research, 2020, roč. 40, č. 4, s. 2209-2217. ISSN 0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.14182.

@article{1668824,
   author = {Svaton, Martin and Zemanova, Milada and Zemanova, Petra and Kultan, Juraj and Fischer, Ondrej and Skřičková, Jana and Jakubíková, Lenka and Cernovska, Marketa and Hrnciarik, Michal and Jirousek, Michal and Krejci, Jana and Krejci, Daniel and Bílek, Ondřej and Blazek, Jiri and Hurdálková, Karolína and Bařinová, Magda and Melichar, Bohuslav},
   article_location = {Athens},
   article_number = {4},
   doi = {http://dx.doi.org/10.21873/anticanres.14182},
   keywords = {Nivolumab; non-small cell lung cancer; corticoids; antibiotics; proton pump inhibitors; NSAID; statins; metformin},
   language = {eng},
   issn = {0250-7005},
   journal = {Anticancer Research},
   title = {Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer},
   url = {http://ar.iiarjournals.org/content/40/4/2209.abstract},
   volume = {40},
   year = {2020}
}

TY  - JOUR
ID  - 1668824
AU  - Svaton, Martin - Zemanova, Milada - Zemanova, Petra - Kultan, Juraj - Fischer, Ondrej - Skřičková, Jana - Jakubíková, Lenka - Cernovska, Marketa - Hrnciarik, Michal - Jirousek, Michal - Krejci, Jana - Krejci, Daniel - Bílek, Ondřej - Blazek, Jiri - Hurdálková, Karolína - Bařinová, Magda - Melichar, Bohuslav
PY  - 2020
TI  - Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer
JF  - Anticancer Research
VL  - 40
IS  - 4
SP  - 2209-2217
EP  - 2209-2217
PB  - International Institute of Anticancer Research
SN  - 02507005
KW  - Nivolumab
KW  - non-small cell lung cancer
KW  - corticoids
KW  - antibiotics
KW  - proton pump inhibitors
KW  - NSAID
KW  - statins
KW  - metformin
UR  - http://ar.iiarjournals.org/content/40/4/2209.abstract
L2  - http://ar.iiarjournals.org/content/40/4/2209.abstract
N2  - Aim: To investigate potential association between administration of corticosteroids, antibiotics, probiotics, proton pump inhibitors, non-steroidal anti-inflammatory drugs (NSAID), statins and metformin and outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Patients and Methods: A total of 224 patients with advanced NSCLC treated at nine comprehensive cancer centers were analyzed in this national retrospective study. Survival statistics were evaluated using Kaplan-Meier method and Cox analysis. Results: Only corticosteroid use had a significant negative effect on the objective response rate. In the univariate analysis, there was no significant effect of the studied concomitant medications on the efficacy of nivolumab. In a subsequent multifactorial analysis, a possible positive effect of the concomitant use of NSAID at the initiation of nivolumab treatment was revealed. Conclusion: The results of the present retrospective exploratory analysis underscore the importance of knowing the exact type of concomitant medication, the route of administration, the dose of medication, and the region of the ongoing study. The present data indicated a significantly higher rate of progression in patients treated with corticosteroids and the possible positive effect of NSAID use at the initiation of nivolumab treatment.
ER  -

SVATON, Martin, Milada ZEMANOVA, Petra ZEMANOVA, Juraj KULTAN, Ondrej FISCHER, Jana SKŘIČKOVÁ, Lenka JAKUBÍKOVÁ, Marketa CERNOVSKA, Michal HRNCIARIK, Michal JIROUSEK, Jana KREJCI, Daniel KREJCI, Ondřej BÍLEK, Jiri BLAZEK, Karolína HURDÁLKOVÁ, Magda BAŘINOVÁ a Bohuslav MELICHAR. Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer. \textit{Anticancer Research}. Athens: International Institute of Anticancer Research, 2020, roč.~40, č.~4, s.~2209-2217. ISSN~0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.14182.

Podrobný výpis o publikaci